Trial Profile
Epigenetic Reprogramming in Relapse AML: A Phase 1 Study of Decitabine and Vorinostat Followed by Fludarabine, Cytarabine and G-CSF (FLAG) in Children and Young Adults With Relapsed/Refractory AML
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Jun 2022
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; Vorinostat (Primary) ; Cytarabine; Filgrastim; Filgrastim; Fludarabine
- Indications Acute myeloid leukaemia; Myeloid leukaemia
- Focus Adverse reactions
- 22 Jun 2022 Status changed from active, no longer recruiting to completed.
- 07 Sep 2021 Planned End Date changed from 1 Apr 2021 to 1 Dec 2021.
- 07 Sep 2021 Status changed from recruiting to active, no longer recruiting.